Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mesenchymal CTC Ratio Dynamics Predicts Response and Survival in Pancreatic Ductal Adenocarcinoma With Neoadjuvant/Conversion Therapy: a Large Single-center Retrospective Cohort Study

NCT07329920 is registered in ClinicalTrials.gov with Guo ShiWei as lead sponsor.

NCT NCT07329920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07329920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mesenchymal CTC Ratio Dynamics Predicts Response and Survival in Pancreatic Ductal Adenocarcinoma With Neoadjuvant/Conversion Therapy: a Large Single-center Retrospective Cohort Study
Lead sponsor
Guo ShiWei
Phase
Observational
Overall status
Completed
Start date
July 10, 2018
Completion date
October 1, 2025
Enrollment
300 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

circulating tumor cells (ctcs), neoadjuvant therapy, pancreatic ductal adenocarcinoma (pdac)